Acute Treatment of Migraine study: Rimegepant
Official title A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine
ClinicalTrials.gov ID: NCT07609914
What this study is testing
What is Rimegepant?
Rimegepant is an investigational oral tablet being studied for the acute treatment of migraine, including the safety of taking a second dose if needed. Rimegepant is designed to block the CGRP receptor, which is involved in migraine pain signaling.
Also referred to as Nurtec ODT.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to see if it is safe and well-tolerated to take a second dose of rimegepant if the first dose does not fully stop a migraine.
- Who it's for
- Adults who have migraines and are currently using rimegepant for acute treatment.
- What's involved
- Participants will take rimegepant for a migraine attack and may take a second dose if their headache returns, while researchers monitor for any side effects.
- Time commitment
- The source text does not specify the total duration or number of visits required.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Eligible participants include adult participants aged 18 years of age or older with a minimum 1-year history of migraine (with or without aura)...
- Participants with headaches occurring ≥15 days per month (migraine or non-migraine) on average across the 12 weeks prior to the Screening Visit and...
The study team makes the final eligibility decision.
Where it is enrolling
- Canoga Park, California, United States
- Fresno, California, United States
- Los Angeles, California, United States
- Boca Raton, Florida, United States
- Miami, Florida, United States
- Orlando, Florida, United States
- Worcester, Massachusetts, United States
- Ann Arbor, Michigan, United States
- Burnsville, Minnesota, United States
- Ridgeland, Mississippi, United States
- Las Vegas, Nevada, United States
- Greensboro, North Carolina, United States
- Austin, Texas, United States
- Dallas, Texas, United States
- Lake Jackson, Texas, United States
- McLean, Virginia, United States
- Jerusalem, Jerusalem, Israel
- Tel Aviv, Israel
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Canoga Park, California, United States; Fresno, California, United States; Los Angeles, California, United States; Boca Raton, Florida, United States; Miami, Florida, United States; Orlando, Florida, United States and 12 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.